MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 561367 | Name: Lisofylline (racemic)
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Lisofylline, also known as LSF, improves cellular mitochondrial function and blocks interleukin-12 (IL-12) signaling and STAT-4 activation in target cells and tissues. IL-12 and STAT-4 activation are important pathways linked to inflammation and autoimmune damage to insulin producing cells. Therefore, LSF and related analogs could provide a new therapeutic approach to prevent or reverse type 1 diabetes.

Chemical Structure

Lisofylline (racemic)
CAS#6493-06-7 (racemic)

Theoretical Analysis

MedKoo Cat#: 561367

Name: Lisofylline (racemic)

CAS#: 6493-06-7 (racemic)

Chemical Formula: C13H20N4O3

Exact Mass: 280.1535

Molecular Weight: 280.33

Elemental Analysis: C, 55.70; H, 7.19; N, 19.99; O, 17.12

Price and Availability

Size Price Availability Quantity
25mg USD 350.00 2 Weeks
50mg USD 625.00 2 Weeks
100mg USD 950.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
6493-06-7 (racemic) 100324-81-0 (R-isomer)
Synonym
LSF; Lisofylline; Lisofylline; CT 1501R; ProTec;
IUPAC/Chemical Name
1-[5-Hydroxyhexyl]-3,7-dimethyl-3,7-dihydro-1H-purine-2,6-dione
InChi Key
NSMXQKNUPPXBRG-UHFFFAOYSA-N
InChi Code
InChI=1S/C13H20N4O3/c1-9(18)6-4-5-7-17-12(19)10-11(14-8-15(10)2)16(3)13(17)20/h8-9,18H,4-7H2,1-3H3
SMILES Code
O=C(N1CCCCC(O)C)N(C)C2=C(N(C)C=N2)C1=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
(±)-Lisofylline ((±)-Lisophylline) is the racemate of Lisofylline. Lisofylline inhibits the generation of phosphatidic acid and free fatty acids.
In vitro activity:
GRMS-55 is a potent hrPDE7A and hrPDE1B inhibitor, while (±)-LSF most strongly inhibits hrPDE3A and hrPDE4B. Reference: Pharm Res. 2020 Jan 2;37(2):19. https://pubmed.ncbi.nlm.nih.gov/31899535/
In vivo activity:
Mice were divided into 4 groups; the first group was fed regular chow diet, the second was fed regular chow diet and treated with LSF (lisofylline), the third was fed high fat diet (HFD), and the fourth was fed HFD and treated with LSF. LSF alleviated obesity-induced cardiac injury indirectly by improving both pancreatic β-cell function and insulin sensitivity, as well as, directly via upregulation of cardiac AMPK expression and downregulation of cardiac inflammation and apoptosis. Reference: Cytokine. 2021 Feb;138:155398. https://pubmed.ncbi.nlm.nih.gov/33341003/
Solvent mg/mL mM comments
Solubility
DMF 10.0 36.67
DMSO 55.0 196.20
Ethanol 2.0 7.13
PBS (pH 7.2) 1.0 3.57
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 280.33 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Świerczek A, Pociecha K, Ślusarczyk M, Chłoń-Rzepa G, Baś S, Mlynarski J, Więckowski K, Zadrożna M, Nowak B, Wyska E. Comparative Assessment of the New PDE7 Inhibitor - GRMS-55 and Lisofylline in Animal Models of Immune-Related Disorders: A PK/PD Modeling Approach. Pharm Res. 2020 Jan 2;37(2):19. doi: 10.1007/s11095-019-2727-z. Erratum in: Pharm Res. 2020 Jan 21;37(3):37. PMID: 31899535; PMCID: PMC6940354. 2. Striffler JS, Nadler JL. Lisofylline, a novel anti-inflammatory agent, enhances glucose-stimulated insulin secretion in vivo and in vitro: studies in prediabetic and normal rats. Metabolism. 2004 Mar;53(3):290-6. doi: 10.1016/j.metabol.2003.10.008. PMID: 15015139. 3. Ali M, Bakr MH, Abdelzaher LA, Sayed SA, Mali V, Desai AA, Radwan E. Lisofylline mitigates cardiac inflammation in a mouse model of obesity through improving insulin secretion and activating cardiac AMPK signaling pathway. Cytokine. 2021 Feb;138:155398. doi: 10.1016/j.cyto.2020.155398. Epub 2020 Dec 16. PMID: 33341003. 4. Świerczek A, Wyska E, Baś S, Woyciechowska M, Mlynarski J. PK/PD studies on non-selective PDE inhibitors in rats using cAMP as a marker of pharmacological response. Naunyn Schmiedebergs Arch Pharmacol. 2017 Oct;390(10):1047-1059. doi: 10.1007/s00210-017-1406-z. Epub 2017 Jul 20. PMID: 28730281; PMCID: PMC5599463.
In vitro protocol:
1. Świerczek A, Pociecha K, Ślusarczyk M, Chłoń-Rzepa G, Baś S, Mlynarski J, Więckowski K, Zadrożna M, Nowak B, Wyska E. Comparative Assessment of the New PDE7 Inhibitor - GRMS-55 and Lisofylline in Animal Models of Immune-Related Disorders: A PK/PD Modeling Approach. Pharm Res. 2020 Jan 2;37(2):19. doi: 10.1007/s11095-019-2727-z. Erratum in: Pharm Res. 2020 Jan 21;37(3):37. PMID: 31899535; PMCID: PMC6940354. 2. Striffler JS, Nadler JL. Lisofylline, a novel anti-inflammatory agent, enhances glucose-stimulated insulin secretion in vivo and in vitro: studies in prediabetic and normal rats. Metabolism. 2004 Mar;53(3):290-6. doi: 10.1016/j.metabol.2003.10.008. PMID: 15015139.
In vivo protocol:
1. Ali M, Bakr MH, Abdelzaher LA, Sayed SA, Mali V, Desai AA, Radwan E. Lisofylline mitigates cardiac inflammation in a mouse model of obesity through improving insulin secretion and activating cardiac AMPK signaling pathway. Cytokine. 2021 Feb;138:155398. doi: 10.1016/j.cyto.2020.155398. Epub 2020 Dec 16. PMID: 33341003. 2. Świerczek A, Wyska E, Baś S, Woyciechowska M, Mlynarski J. PK/PD studies on non-selective PDE inhibitors in rats using cAMP as a marker of pharmacological response. Naunyn Schmiedebergs Arch Pharmacol. 2017 Oct;390(10):1047-1059. doi: 10.1007/s00210-017-1406-z. Epub 2017 Jul 20. PMID: 28730281; PMCID: PMC5599463.
1: Jung HS, Kaplan LJ, Park PK. Reviewing the studies of the National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome Network: outcomes and clinical findings. Curr Probl Surg. 2013 Oct;50(10):451-62. doi: 10.1067/j.cpsurg.2013.08.009. Review. PubMed PMID: 24156843. 2: Jain R, DalNogare A. Pharmacological therapy for acute respiratory distress syndrome. Mayo Clin Proc. 2006 Feb;81(2):205-12. Review. PubMed PMID: 16471076. 3: Yang Z, Chen M, Nadler JL. Lisofylline: a potential lead for the treatment of diabetes. Biochem Pharmacol. 2005 Jan 1;69(1):1-5. Review. PubMed PMID: 15588708. 4: Wiedemann HP, Arroliga AC, Komara JJ Jr. Emerging systemic pharmacologic approaches in acute respiratory distress syndrome. Respir Care Clin N Am. 2003 Dec;9(4):419-35. Review. PubMed PMID: 14984064. 5: Bhandari V. Developmental differences in the role of interleukins in hyperoxic lung injury in animal models. Front Biosci. 2002 Jul 1;7:d1624-33. Epub 2002 Jul 1. Review. PubMed PMID: 12108429. 6: Sturm A, Dignass AU. Modulation of gastrointestinal wound repair and inflammation by phospholipids. Biochim Biophys Acta. 2002 May 23;1582(1-3):282-8. Review. PubMed PMID: 12069839. 7: Bright JJ, Sriram S. Immunotherapy of inflammatory demyelinating diseases of the central nervous system. Immunol Res. 2001;23(2-3):245-52. Review. PubMed PMID: 11444389. 8: Nemunaitis J. Recombinant hematopoietic growth factors in bone marrow transplantation. Cancer Treat Res. 1995;76:225-48. Review. PubMed PMID: 7577337.